Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study
Open accessAbstract
Nonalcoholic steatohepatitis (NASH) is a common chronic liver disease that may advance to fibrosis and lead to mortality; however, no pharmacotherapy is currently available. We tested the hypothesis that inhibition of both the sodium–glucose cotransporters 1 and 2 with licogliflozin would lead to improvement in NASH. A total of 107 patients with phenotypic or histologic NASH were randomized (1:2:2) to receive oral administration of either placebo (n = 21), licogliflozin 30 mg (n = 43) or 150 mg (n = 43) once daily for 12 weeks. Licogliflozin 150 mg showed a significant 32% (80% confidence interval (CI): 21–43%; P = 0.002) placebo-adjusted reduction in serum alanine aminotransferase after 12 weeks of treatment, the primary endpoint of the study. However, the 30 mg dose of licogliflozin did not meet the primary endpoint (placebo-adjusted reduction 21% (80% CI: 7–32%; P = 0.061)). Diarrhea occurred in 77% (33 of 43), 49% (21 of 43) and 43% (9 of 21) of patients treated with licogliflozin 150 mg, 30 mg and placebo, respectively, which was mostly mild in severity. No other major safety concerns were identified. Treatment with 150 mg licogliflozin led to reductions in serum alanine aminotransferase in patients with NASH. Studies of longer duration and in combination with drugs that have different mechanisms of action are needed to validate these findings and to define a role of licogliflozin as a therapeutic option for NASH. ClinicalTrials.gov identifier: NCT03205150. In a phase 2a clinical trial in patients with nonalcoholic steatohepatitis, dual inhibition of sodium–glucose cotransporters 1 and 2 with 150 mg of licogliflozin led to reductions in serum alanine aminotranferase levels.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In a small-scale pilot study, empagliflozin reduced steatosis, ballooning and fibrosis after 24 weeks in people with type 2 diabetes and MASH compared to pre-treatment and historical control.
“In a small-scale pilot study, empagliflozin reduced steatosis, ballooning and fibrosis after 24 weeks of treatment in people with type 2 diabetes and MASH when compared to pre-treatment and a historical control group (BMI reduction of 0.7 kg/m 2 , total body weight not provided) [158].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [158]
The Abstract reports a 24-week empagliflozin study with reduced steatosis only in a subgroup, but says its participants had NAFLD without type 2 diabetes and were compared with placebo. The Discussion reports reduced liver stiffness, a surrogate for fibrosis; it does not report improvements in ballooning or a comparison with a historical control group. No page numbers are available in our copy. (LLM, conf=0.88)
Experimental — accuracy not yet measuredReductions in ALT were shown with empagliflozin and licogliflozin.
“Reductions in ALT were shown with empagli fl ozin 414 and licogli fl ozin.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [417]
Clinical evidence for SGLT2 inhibitors specifically as NASH treatment is currently limited.
“However, clinical evidence on SGLT2 inhibitors as a treatment specifically for NASH is currently limited.126”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [126]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239 · see citing works
Self-citationGlobal burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · see citing works
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836 · see citing works
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354 · see citing works
Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492 · see citing works
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237 · see citing works
Non-alcoholic fatty liver disease - a global public health perspective
Younossi, Z. M. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.033 · Cited by 2,149 · see citing works
Williams, C. D., Stengel, J. Z., Asike, M., Torres, D. M., Shaw, J. C., Contreras, M., Landt, C. L., & Harrison, S. A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.09.038 · Cited by 2,146 · see citing works
Self-citationHarrison, S. A., Bashir, M. R., Guy, C. D., Zhou, R., Moylan, C. A., Frias, J. P., Alkhouri, N., Bansal, M. B., Baum, S., Neuschwander-Tetri, B. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32517-6 · Cited by 802 · see citing works
Self-citationInsulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease
Smith, G. I., Shankaran, M., Yoshino, M., Schweitzer, G. G., Chondronikola, M., Beals, J. W., Okunade, A. L., Patterson, B. W., Nyangau, E., Field, T., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134165 · Cited by 771 · see citing works
Self-citationKuchay, M. S., Krishan, S., Mishra, S. K., Farooqui, K. J., Singh, M. K., Wasir, J. S., Bansal, B., Kaur, P., Jevalikar, G., Gill, H. K., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0165 · Cited by 662 · see citing works
Lassailly, G., Caiazzo, R., Ntandja-Wandji, L.-C., Gnemmi, V., Baud, G., Verkindt, H., Ningarhari, M., Louvet, A., Leteurtre, E., Raverdy, V., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.06.006 · Cited by 622 · see citing works
Stenlöf, K., Cefalu, W. T., Kim, K., Alba, M., Usiskin, K., Tong, C., Canovatchel, W. J., & Meininger, G. E. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12054 · Cited by 613 · see citing works
Harrison, S. A., Rinella, M. E., Abdelmalek, M. F., Trotter, J. F., Paredes, A. H., Arnold, H. L., Kugelmas, M., Bashir, M. R., Jaros, M. J., Ling, L., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30474-4 · Cited by 425 · see citing works
Self-citationEriksson, J. W., Lundkvist, P., Jansson, P.-A., Johansson, L., Kvarnström, M., Moris, L., Miliotis, T., Forsberg, G.-B., Risérus, U., Lind, L., et al. (2018) · Diabetologia · doi:10.1007/s00125-018-4675-2 · Cited by 396 · see citing works
Shimizu, M., Suzuki, K., Kato, K., Jojima, T., Iijima, T., Murohisa, T., Iijima, M., Takekawa, H., Usui, I., Hiraishi, H., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13520 · Cited by 393 · see citing works
Loomba, R., Kayali, Z., Noureddin, M., Ruane, P., Lawitz, E. J., Bennett, M., Wang, L., Harting, E., Tarrant, J. M., McColgan, B. J., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.07.027 · Cited by 340 · see citing works
Self-citationYokoo, T., Bydder, M., Hamilton, G., Middleton, M. S., Gamst, A. C., Wolfson, T. J., Hassanein, T., Patton, H. M., Lavine, J. E., Schwimmer, J. B., et al. (2009) · Radiology · doi:10.1148/radiol.2511080666 · Cited by 303 · see citing works
Estimation of Hepatic Proton-Density Fat Fraction by Using MR Imaging at 3.0 T
Yokoo, T., Shiehmorteza, M., Hamilton, G., Wolfson, T. J., Schroeder, M. E., Middleton, M. S., Bydder, M., Gamst, A. C., Kono, Y., Kuo, A., et al. (2011) · Radiology · doi:10.1148/radiol.10100659 · Cited by 291 · see citing works
Lifestyle modification in NAFLD/NASH: Facts and figures
Hallsworth, K., & Adams, L. A. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.10.008 · Cited by 266 · see citing works
Lawitz, E. J., Coste, A., Poordad, F., Alkhouri, N., Loo, N., McColgan, B. J., Tarrant, J. M., Nguyen, T., Han, L., Chung, C., et al. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.04.042 · Cited by 217 · see citing works
Taheri, H., Malek, M., Ismail‐Beigi, F., Zamani, F., Sohrabi, M., Babaei, M. R., & Khamseh, M. E. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01498-5 · Cited by 197 · see citing works
Pathogenesis and novel treatment options for non-alcoholic steatohepatitis
Wong, V. W., Chitturi, S., Wong, G. L., Yu, J. Q., Chan, H. L., & Farrell, G. C. (2016) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(16)30011-5 · Cited by 186 · see citing works
Poulsen, S. B., Fenton, R. A., & Rieg, T. (2015) · Current Opinion in Nephrology and Hypertension · doi:10.1097/mnh.0000000000000152 · Cited by 164 · see citing works
Raj, H., Durgia, H., Palui, R., Kamalanathan, S., Selvarajan, S., Kar, S. S., & Sahoo, J. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i2.114 · Cited by 97 · see citing works
Xie, Q., Zhou, X., Huang, P., Wei, J., Wang, W., & Zheng, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092772 · Cited by 84 · see citing works
He, Y., Haynes, W., Meyers, C. D., Amer, A., Zhang, Y., Mahling, P., Mendonza, A. E., Ma, S., Chutkow, W., & Bachman, E. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13654 · Cited by 81 · see citing works
Self-citationSeko, Y., Nishikawa, T., Umemura, A., Yamaguchi, K., Moriguchi, M., Yasui, K., Kimura, M., Iijima, H., Hashimoto, T., Sumida, Y., et al. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s184767 · Cited by 80 · see citing works
Reproducibility of hepatic fat fraction measurement by magnetic resonance imaging
Mashhood, A., Railkar, R. A., Yokoo, T., Levin, Y. S., Clark, L., Fox‐Bosetti, S., Middleton, M. S., Riek, J. K., Kauh, E. A., Dardzinski, B. J., et al. (2012) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.23928 · Cited by 74 · see citing works
SGLT2 Inhibitors in Liver Patients
Hsiang, J. C., & Wong, V. W.-S. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.05.021 · Cited by 48 · see citing works
Bays, H. E., Kozlovski, P., Shao, Q., Proot, P., & Keefe, D. (2020) · Obesity · doi:10.1002/oby.22764 · Cited by 41 · see citing works
He, Y., Schofield, J. P., Mahling, P., Mendonza, A. E., & Hinder, M. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1840 · Cited by 8 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210 · see citing works
(2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 510 · see citing works
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
Tacke, F., Puengel, T., Loomba, R., & Friedman, S. L. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.038 · Cited by 321 · see citing works
Liver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies
Parola, M., & Pinzani, M. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101231 · Cited by 226 · see citing works
FXR agonists in NASH treatment
Adorini, L., & Trauner, M. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.034 · Cited by 197 · see citing works
Eslam, M., Fan, J., Yu, M., Wong, V. W., Cua, I. H., Liu, C., Tanwandee, T., Gani, R. A., Seto, W., Alam, S., et al. (2025) · Hepatology International · doi:10.1007/s12072-024-10774-3 · Cited by 186 · see citing works
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Huttasch, M., Roden, M., & Kahl, S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155937 · Cited by 169 · see citing works
Lin, J., Huang, Y., Xu, B., Gu, X., Huang, J., Sun, J., Jia, L., Jiang, H., Huang, C., Wei, X., et al. (2025) · BMJ · doi:10.1136/bmj-2024-083735 · Cited by 145 · see citing works
Byrne, C. D., Armandi, A., Pellegrinelli, V., Vidal‐Puig, A., & Bugianesi, E. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01045-z · Cited by 109 · see citing works
Targeting SLC transporters: small molecules as modulators and therapeutic opportunities
Schlessinger, A., Zatorski, N., Hutchinson, K., & Colas, C. (2023) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2023.05.011 · Cited by 87 · see citing works
Lopez, A., & Pajimna, J. A. T. (2024) · Scientific Reports · doi:10.1038/s41598-024-52603-5 · Cited by 91 · see citing works
Dysregulation of Lipid and Glucose Metabolism in Nonalcoholic Fatty Liver Disease
Bhat, N., & Mani, A. (2023) · Nutrients · doi:10.3390/nu15102323 · Cited by 76 · see citing works
Mejía-Guzmán, J. E., Belmont-Hernández, R. A., Chávez-Tapia, N. C., Uribe, M., & Nuño‐Lámbarri, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26072959 · Cited by 72 · see citing works
Antioxidant and anti-inflammatory agents in chronic liver diseases: Molecular mechanisms and therapy
Zhang, C., Liu, S., & Yang, M. J. (2023) · World Journal of Hepatology · doi:10.4254/wjh.v15.i2.180 · Cited by 71 · see citing works
Nonalcoholic fatty liver disease: Current therapies and future perspectives in drug delivery
Domingues, I., Leclercq, I. A., & Beloqui, A. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.040 · Cited by 45 · see citing works
Bica, I.-C., Stoica, R. A., Salmen, T., Janež, A., Volčanšek, Š., Popovic, D. S., Muzurović, E. M., Rizzo, M., & Stoian, A. P. (2023) · Medicina · doi:10.3390/medicina59061136 · Cited by 42 · see citing works
The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
Finney, A. C., Das, S., Kumar, D., McKinney, M. P., Cai, B., Yurdagul, A., & Rom, O. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1116861 · Cited by 40 · see citing works
Pharmacological treatment of MASLD: contemporary treatment and future perspectives
Drygalski, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136518 · Cited by 39 · see citing works
Molecular Aspects of MAFLD—New Insights on Pathogenesis and Treatment
Filipović, B. F., Marjanovic-Haljilji, M., Mijac, D. D., Lukić, S., Kapor, S., Kapor, S., Starčević, A., Popovic, D. D., & Djoković, A. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45110573 · Cited by 34 · see citing works
Oligonucleotide therapies for nonalcoholic steatohepatitis
Li, S., Xiong, F., Zhang, S., Liu, J., Gao, G., Xie, J. H., & Wang, Y. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102184 · Cited by 32 · see citing works
Hu, Y., Sun, C., Chen, Y., Liu, Y., & Fan, J. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2024.00123 · Cited by 32 · see citing works
Potential therapeutic strategies for MASH: from preclinical to clinical development
Xie, Z., Li, Y., Cheng, L., Huang, Y., Rao, W., Shi, H., & Li, J. (2024) · Life Metabolism · doi:10.1093/lifemeta/loae029 · Cited by 31 · see citing works
Drug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and direction
Zhou, D., & Fan, J. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003355 · Cited by 25 · see citing works
HFpEF and MASLD: converging mechanisms and clinical implications
Capone, F., Häseli, S. P., Liu, L., Strocchi, S., Langenberg, C., Lusis, A. J., Pietzner, M., Muoio, D. M., Rider, O. J., Raman, B., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01257-z · Cited by 32 · see citing works
Inter-organ metabolic interaction networks in non-alcoholic fatty liver disease
Fan, Y., Zhang, S., Wang, Y., Wang, H., Li, H., & Bai, L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1494560 · Cited by 25 · see citing works
Colosimo, S., Tan, G. D., Petroni, M. L., Marchesini, G., & Tomlinson, J. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.12.010 · Cited by 25 · see citing works
Mao, T., Sun, Y., Xu, X., & He, K. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000234 · Cited by 24 · see citing works
Review of current and new drugs for the treatment of metabolic-associated fatty liver disease
Gish, R. G., Fan, J., Dossaji, Z., Fichez, J., Laeeq, T., Chun, M. J., & Boursier, J. (2024) · Hepatology International · doi:10.1007/s12072-024-10698-y · Cited by 24 · see citing works
Wan, X., Ma, J., Bai, H., Hu, X., Ma, Y., Zhao, M., Liu, J., & Duan, J. (2025) · Biomolecules · doi:10.3390/biom15010140 · Cited by 22 · see citing works
Li, H., Hou, Y., Xin, W., Ding, L., Yang, Y., Zhang, Y., Wu, W., Wang, Z., & Ding, W. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107647 · Cited by 22 · see citing works
Self-citationKakazu, E., Mino, M., & Kanto, T. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0048 · Cited by 22 · see citing works
Zhao, Z., Tong, Y., Jiang, W., Zang, Y., Xiong, J., Li, J. X., & Hu, J. (2023) · Journal of Natural Products · doi:10.1021/acs.jnatprod.3c00181 · Cited by 21 · see citing works
Zhong, J., Cai, Z., Zhu, G., & Zhang, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16348 · Cited by 18 · see citing works
Jamalinia, M., Saeian, S., Nikkhoo, N., Nazerian, A., & Lankarani, K. B. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.131 · Cited by 17 · see citing works
Drug Pipeline for MASLD: What Can Be Learned from the Successful Story of Resmetirom
Knezović, E., Hefer, M., Blažanović, S., Petrović, A., Tomičić, V., Srb, N., Kirner, D., Smolić, R., & Smolić, M. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47030154 · Cited by 16 · see citing works
Li, Y., Lei, R., Lei, H., Qin, X., Xie, F., Yao, C., & Feng, P. (2022) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002471 · Cited by 15 · see citing works
Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies
Hao, C. H. E. N., Zhou, Y., Hao, H., & XIONG, J. (2024) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(24)60690-4 · Cited by 15 · see citing works
Fan, X., Wang, Y., Wang, Y., Duan, H., Du, Y., Pan, T., & Zhong, X. (2025) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-025-00898-z · Cited by 10 · see citing works
Morawska, A., Frankowski, R., Grabarczyk, M., Kosmalski, M., & Różycka-Kosmalska, M. (2025) · Life · doi:10.3390/life15111713 · Cited by 8 · see citing works
Kaur, S., Sojitra, V., Zahra, A., Hutchinson, J., Folawemi, O., Bittla, P., & Ramphall, S. (2023) · Cureus · doi:10.7759/cureus.45789 · Cited by 7 · see citing works
Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease Cross Talk
Nysather, J. A., Kaya, E., Manka, P. P., Gudsoorkar, P. S., & Syn, W. (2023) · Advances in Kidney Disease and Health · doi:10.1053/j.akdh.2023.04.001 · Cited by 7 · see citing works
de Souza, M. H. G., Amaral, M. J. M., Lima, L. C. V., & Villela‐Nogueira, C. A. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18498 · Cited by 6 · see citing works
Dobbie, L. J., Cuthbertson, D. J., Hydes, T., Alam, U., & Zhao, S. S. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad068 · Cited by 6 · see citing works
Synthetic Approaches to Gliflozins: A Comprehensive Overview
Nahide, P. D., Ratnamala, A., Bandichhor, R., Sasikala, C. V. A., Beesu, M., Biswas, S., Basu, D., & Achanta, S. (2024) · Synthesis · doi:10.1055/s-0042-1751524 · Cited by 6 · see citing works
Dysfunctional glucose metabolism triggers oxidative stress to induce kidney injury in diabetes
Gao, M., Dai, M.-T., & Gong, G. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i4.102554 · Cited by 6 · see citing works
Misceo, D., Mocciaro, G., D’Amore, S., & Vacca, M. (2024) · Nutrition & Metabolism · doi:10.1186/s12986-024-00871-3 · Cited by 6 · see citing works
Procyk, G., Jaworski, J., Gąsecka, A., Filipiak, K. J., & Borovac, J. A. (2024) · Advances in Medical Sciences · doi:10.1016/j.advms.2024.09.001 · Cited by 6 · see citing works
Xie, T., & Zhao, L.-J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116343 · Cited by 5 · see citing works
Zaki, A. M., Abo‐elnour, D. E., Abdalla, Y. E., Hassan, R. Y., Salama, M. K., Elboraay, T., & Abdelhaleem, I. A. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102657 · Cited by 4 · see citing works
Yi, J., Patel, K., Miller, R. J. H., Marcinkiewicz, A. M., Shanbhag, A. D., Hijazi, W., Dharmavaram, N. L., Lemley, M. H., Zhou, J., Zhang, W., et al. (2025) · medRxiv · doi:10.1101/2025.06.09.25329157 · Cited by 4 · see citing works
Tang, M., Ma, Y., & Wang, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1829315 · Cited by 3 · see citing works
Luong, T. V., Tran, H., Thi, B. N. C., Vu, H. M., Le, T., Le, T., Thi, H. N., Nguyen, H. M., Doan, T. C., Ho, A. B., et al. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i7.107751 · Cited by 5 · see citing works
Kostitska, I. O., Protas, N., & Petrovska, L. (2023) · Diabetes Obesity Metabolic Syndrome · doi:10.57105/2415-7252-2023-5-01 · Cited by 3 · see citing works
Mao, X., Fan, H., Yuen, M.-F., Cheung, R. C., Seto, W., & Nguyen, M. H. (2026) · Hepatology · doi:10.1097/hep.0000000000001771 · Cited by 3 · see citing works
Liao, X.-M., Gongpan, P., Wu, S., Li, T.-Z., Li, X., Li, X., Wang, L.-L., & Geng, C. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108613 · Cited by 2 · see citing works
Experimental Workflow for Preclinical Studies of Human Antifibrotic Therapies
Reolizo, L., Matsuda, M., & Seki, E. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3207-9_18 · Cited by 2 · see citing works
Fawwad, S. H. U., Patel, M. S., Dziugieł, S., Alfaki, R., Shaikh, M. T. A., Khanal, K., Lamichhane, P., & Baral, S. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000003826 · Cited by 1 · see citing works
Berecz, G., Dancsó, A., Lauritz, M. T., Kiss, L., Simig, G., & Volk, B. (2025) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.21.205 · Cited by 1 · see citing works
Tawai, J., & Xiong, J. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01756-2 · Cited by 1 · see citing works
Tsutsumi, T., Tang, N. S. Y., Ng, C. H., Suzuki, H., Syn, N. L., Sasikumar, N. A., Ho, G. J. K., Chua, D., Tioh, J. K., Pramotedham, T., et al. (2026) · Med · doi:10.1016/j.medj.2026.101077 · Cited by 1 · see citing works
Qiu, H., Tan, X., Sheng, Q., Yang, N., Jiang, C. M., & Wang, L. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118096 · Cited by 2 · see citing works
Pharmacologic treatment of NAFLD/NASH and their related comorbidities
Kim, S. H., & Kwo, P. Y. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99649-5.00013-3
Liver Steatosis: From Lipotoxicity to Cellular Damage
Puengel, T., & Tacke, F. (2024) · Springer eBooks · doi:10.1007/978-981-97-9519-2_4 · Cited by 1 · see citing works
Lv, X., Mi, D. M., Xin, Y., Dong, W., & Wang, D. (2025) · Hepatitis Monthly · doi:10.5812/hepatmon-153404
Zabotina, E. E., Khabarova, Y. A., & Stukova, N. Y. (2025) · Experimental and Clinical Gastroenterology · doi:10.31146/1682-8658-ecg-229-9-96-109
de Souza, M. H. G., Al‐Sharif, L., Khalil, S. M., & Diaz, I. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.103173
Huang, S., Xi, Y., Hong, Y., & Hu, C. (2025) · Hormone and Metabolic Research · doi:10.1055/a-2720-5290
Kidoguchi, S., Kitada, K., Morishita, A., Tsuji, Y., Ohsaki, H., Yamazaki, D., Morikawa, T., Konishi, Y., Kobara, H., Yokoo, T., et al. (2025) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2025.12.006
Imran, J., Hassan, H., Zannat, T., Ghosh, P., Afsana, F., Azam, M., Amin, M. F., & Pathan, M. F. (2026) · Bangladesh Journal of Endocrinology and Metabolism · doi:10.4103/bjem.bjem_31_25
Njeim, R., Abureesh, O., Sohail, A., Tam, R., & Deeb, L. S. (2026) · Livers · doi:10.3390/livers6030035
Pharmacotherapy for MASLD: current evidence and challenges in clinical practice
Pages, L., Rojo, D., Jiménez-Masip, A., Tricarico, E., Mas‐Carrió, E., Aguilar, A., Gómez, N., Molinero, L., & Pericas, J. M. (2026) · Annals of Hepatology · doi:10.1016/j.aohep.2026.102477
- Authors
- Harrison, S. A., Manghi, F. P., Smith, W. B., Alpenidze, D., Aizenberg, D., Klarenbeek, N., Chen, C.-Y., Zuckerman, E., Ravussin, E., Charatcharoenwitthaya, P., Cheng, P.-N., Katchman, H., Klein, S., Ben-Ari, Z., Mendonza, A. E., Zhang, Y., Martic, M., Ma, S., Kao, S., Tanner, S., Pachori, A., Badman, M. K., He, Y., Ukomadu, C., & Sicard, E.
- Affiliations
- Pinnacle Clinical Research (US)
- University of Tennessee Medical Center (US)
- Centre for Human Drug Research (NL)
- Chia-Yi Christian Hospital (TW)
- Carmel Medical Center (IL)
- Siriraj Hospital (TH)
- National Cheng Kung University Hospital (TW)
- Tel Aviv Sourasky Medical Center (IL)
- Washington University in St. Louis (US)
- Novartis Institutes for BioMedical Research (CH)
- Corresponding author
- Harrison, Stephen A.
- ORCID
- Venue
- Nature Medicine
- Published
- 2022-06-20
- Volume
- 28
- Issue
- 7
- Pages
- 1432-1438
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC10061496
- OpenAlex
- W4283159936
- Semantic Scholar
- 31e0dca926a9354931f42f36574a95b52a6f20b1
- Cited by
- 75
- References
- 32
- Citations by year
- 2026: 10 · 2025: 26 · 2024: 17 · 2023: 19 · 2022: 3
- FWCI
- 11.73
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Civil War Book Review (submittedVersion)
- Funders
- Novartis Pharmaceuticals
- Topics
- Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- nonalcoholic steatohepatitis, sodium-glucose cotransporter, alanine aminotransferase, liver fibrosis, pharmacotherapy, diarrhea, dose comparison
- MeSH terms
- Alanine Transaminase, Anhydrides, Double-Blind Method, Humans, Sorbitol, Treatment Outcome, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
